WuXi STA’s new oligonucleotide and peptide production facility supports its end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) platform for new modalities
WuXi STA, a subsidiary of WuXi AppTec, has opened a new large-scale facility at its Changzhou campus in China to enable oligonucleotide and peptide manufacturing.
The new manufacturing facility includes a 30,570ft2 oligonucleotide plant and a 22,260ft2 peptide plant.
The oligonucleotide plant features four large-scale oligonucleotide production lines, and more than 20 small-to-mid-scale production lines.
The peptide plant features three new production lines with reactors capable of accommodating up to 1,000L volume.
WuXi STA said that the plant will expand its oligonucleotide development and manufacturing capabilities, and enhance the overall capacity of single synthesis run from 1.9mol to 6mol.
Also, the peptide plant will increase its overall Solid Phase Peptide Synthesis (SPPS) total reactor volume to 6,490L, said the company.
WuXi STA CEO and WuXi AppTec co-CEO Minzhang Chen said: “We are pleased to support our global partners in their efforts to develop new modality therapies for patients in need.
“WuXi STA is committed to enabling partners by enhancing our new modality CRDMO platform’s capacity and capability to expedite the development and commercialization of more innovative therapies to benefit patients worldwide.”
WuXi STA said that the new facility is an important part of its end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) platform for new modalities.
Its platform is said to support the discovery, development and production of oligonucleotides and peptides, including novel monomers and linkers, and complex conjugates.
The company claims that its new modality CRDMO platform helps global partners to progress their projects to late and commercial stages.
WuXi STA is a pharmaceutical development and manufacturing and technology platform company that serves the life sciences industry in Asia, North America and Europe.
The company also offers injectable formulation development and manufacturing services, including Lipid NanoParticle technology (LNP) along with complete analytical and Chemical, Manufacturing, and Controls (CMC) dossier preparation services.
In February last year, WuXi STA signed an agreement with Bristol Myers Squibb to acquire the latter’s manufacturing facility in Couvet, Switzerland.